<- Go Home
Centrexion Therapeutics Corp.
Centrexion Therapeutics Corp. is engaged in identifying, developing, and commercializing biopharmaceutical therapies for the treatment of chronic pain. The company develops and commercializes non-opioid and non-addictive therapies, with a pipeline of drug candidates targeting new or emerging pharmacological targets for pain management. Its portfolio includes CNTX-4975 and CNTX-0290, a human somatostatin receptor 4 agonist. The company conducts clinical trials to evaluate the safety and efficacy of its therapies and holds patents related to its drug candidates. The company was founded in 2013 and is based in Boston, Massachusetts.
Market Cap
N/A
Volume
N/A
Cash and Equivalents
$69.3M
EBITDA
-$7.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$47.5M
Profit Margin
100.00%
52 Week High
N/A
52 Week Low
N/A
Dividend
N/A
Price / Book Value
N/A
Price / Earnings
N/A
Price / Tangible Book Value
N/A
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$7.9M
Return on Equity
14.82%
Return on Assets
-7.23
Cash and Short Term Investments
$69.3M
Debt
$24.4M
Equity
$47.5M
Revenue
$47.5M
Unlevered FCF
-$408.0K
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium